Sussman Amy N, Boyer Thomas D
Department of Medicine, University of Arizona College of Medicine, Tucson, AZ 85724, USA.
Curr Gastroenterol Rep. 2011 Feb;13(1):17-25. doi: 10.1007/s11894-010-0156-6.
One of the most common manifestations of the development of portal hypertension in the patient with cirrhosis is the appearance of ascites. Once ascites develops, the prognosis worsens and the patient becomes susceptible to complications such as bacterial peritonitis, hepatic hydrothorax, hyponatremia, and complications of diuretic therapy. As the liver disease progresses, the ascites becomes more difficult to treat and many patients develop renal failure. Most patients can be managed by diuretics which, when used correctly, will control the ascites. Spontaneous bacterial peritonitis can be treated effectively, but portends a worse prognosis. Once the ascites becomes refractory to diuretics, liver transplantation is the best option, although use of transjugular intrahepatic portosystemic shunts will control the ascites in many patients. Lastly, the development of hepatorenal syndrome indicates the patient's liver disease is advanced, and transplantation again is the best option. However, use of vasoconstrictors may improve renal function in some patients, helping in their management while they await a liver transplant.
肝硬化患者门静脉高压发展最常见的表现之一是腹水的出现。一旦腹水形成,预后就会恶化,患者易发生诸如细菌性腹膜炎、肝性胸水、低钠血症以及利尿治疗并发症等情况。随着肝脏疾病进展,腹水变得更难治疗,许多患者会发展为肾衰竭。大多数患者可用利尿剂治疗,正确使用时能控制腹水。自发性细菌性腹膜炎可得到有效治疗,但预后较差。一旦腹水对利尿剂产生抵抗,肝移植是最佳选择,尽管经颈静脉肝内门体分流术能控制许多患者的腹水。最后,肝肾综合征的出现表明患者的肝脏疾病已处于晚期,移植仍是最佳选择。然而,使用血管收缩剂可能会改善部分患者的肾功能,有助于在他们等待肝移植期间进行管理。